Puma Biotechnology Inc
As of Oct 22, 2026, Puma Biotechnology is in Stage 2, the uptrend phase, now in week 69 (since Jun 11, 2025). It closed at $11.26, at its 52-week high and above its 200-day average, which is rising.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is PBYI early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
PBYI among Biotechnology34th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …34 | PBYI | Stage 2 · wk 69 | 96 | +21.3% |
Puma Biotechnology: quick answers
What stage is Puma Biotechnology in?
As of Oct 22, 2026, Puma Biotechnology (PBYI) is in Stage 2, the uptrend phase. It entered Stage 2 on Jun 11, 2025 and is in week 69. What the four stages mean
Is Puma Biotechnology in an uptrend?
Yes. Puma Biotechnology is in a Stage 2 uptrend. It trades 44.8% above its 200-day average, which is rising.
How far is Puma Biotechnology from its 52-week high?
Puma Biotechnology closed at $11.26 on Oct 22, 2026, at its 52-week high. Its 52-week low is $4.73.
How has Puma Biotechnology performed over the past year?
As of Oct 22, 2026, Puma Biotechnology is up 117.8% over the past year and up 95.1% so far in 2026.
Which sector and industry is Puma Biotechnology in?
Puma Biotechnology is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.